PMID- 36075524
OWN - NLM
STAT- MEDLINE
DCOM- 20220929
LR  - 20220929
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 626
DP  - 2022 Oct 15
TI  - Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer's 
      disease therapy.
PG  - 122167
LID - S0378-5173(22)00721-9 [pii]
LID - 10.1016/j.ijpharm.2022.122167 [doi]
AB  - Despite the efforts of the pharmaceutical and research sectors, Alzheimer's 
      disease (AD) remains incurable, imposing the demand for new effective strategies. 
      Vitamin B12 (VB12) has aroused interest due to its in vitro anti-amyloidogenic 
      properties. However, the high molecular weight and hydrophilicity of VB12 are the 
      main obstacles to its clinical application by hindering its passage through the 
      blood-brain barrier (BBB). In recent years, drug delivery systems (DDSs) capable 
      of transporting molecules across the BBB have gained attention for their 
      effective brain delivery. In this work, VB12-loaded liposomes functionalized with 
      transferrin (Tf) were produced, envisaging the dual-targeting of VB12 to the BBB 
      and neuronal cells, due to the overexpression of Tf receptors in these cells. The 
      produced liposomes presented sizes smaller than 200 nm, with low polydispersity 
      and neutral zeta potential, being suitable for brain delivery. The nanoparticles 
      exhibited an adequate encapsulation efficiency, a sustained release of VB12 for 
      9 days, and physical stability at storage conditions for up to 2 months. The 
      developed nanosystem was capable of delaying the formation of Abeta fibrils and 
      disrupting mature fibrils, highlighting its great potential for the prevention 
      and treatment of AD.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Andrade, Stephanie
AU  - Andrade S
AD  - LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and 
      Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 
      4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, 
      Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 
      Porto, Portugal.
FAU - Ramalho, Maria J
AU  - Ramalho MJ
AD  - LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and 
      Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 
      4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, 
      Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 
      Porto, Portugal.
FAU - Loureiro, Joana A
AU  - Loureiro JA
AD  - LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and 
      Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 
      4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, 
      Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 
      Porto, Portugal. Electronic address: jasl@fe.up.pt.
FAU - Pereira, Maria C
AU  - Pereira MC
AD  - LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and 
      Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 
      4200-465 Porto, Portugal; ALiCE - Associate Laboratory in Chemical Engineering, 
      Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 
      Porto, Portugal. Electronic address: mcsp@fe.up.pt.
LA  - eng
PT  - Journal Article
DEP - 20220906
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Liposomes)
RN  - 0 (Transferrin)
RN  - 0 (Vitamins)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - *Alzheimer Disease/drug therapy
MH  - Blood-Brain Barrier/metabolism
MH  - Delayed-Action Preparations/pharmacology
MH  - Humans
MH  - Liposomes/pharmacology
MH  - *Nanoparticles
MH  - Transferrin/metabolism
MH  - Vitamin B 12
MH  - Vitamins
OTO - NOTNLM
OT  - Amyloid beta-peptide
OT  - Blood-brain barrier
OT  - Brain targeting
OT  - Lipid vesicle
OT  - Nanoparticle
OT  - Targeted delivery
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/09/09 06:00
MHDA- 2022/09/30 06:00
CRDT- 2022/09/08 19:35
PHST- 2022/04/26 00:00 [received]
PHST- 2022/08/11 00:00 [revised]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2022/09/09 06:00 [pubmed]
PHST- 2022/09/30 06:00 [medline]
PHST- 2022/09/08 19:35 [entrez]
AID - S0378-5173(22)00721-9 [pii]
AID - 10.1016/j.ijpharm.2022.122167 [doi]
PST - ppublish
SO  - Int J Pharm. 2022 Oct 15;626:122167. doi: 10.1016/j.ijpharm.2022.122167. Epub 
      2022 Sep 6.